Bromocriptine used in parkinsonism is classified in this group (e.g. tablets of 5 mg and 10 mg). Low strength bromocriptine tablets (e.g. 2.5 mg) used as a prolactine inhibitor are classified in G02CB - Prolactine inhibitors.
Cabergoline used in parkinsonism is classified in this group (e.g. tablets of 1 mg). Low strength cabergoline tablets (0.5 mg) used as a prolactine inhibitor are classified in G02CB.
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is also used in the treatment of Parkinsonism, are classified in G02CB while lisuride in low strength formulations (e.g. 25 mcg tablets) are classified in N02CA.
|
